drug_type
RELEVANT_DRUG
intervention_type
Replicative adenovirus vector (oncolytic virus/biologic)
drug_description
A conditionally replicative oncolytic adenovirus engineered with an RGD-modified fiber to retarget entry to αv integrins (e.g., αvβ3/αvβ5) on pancreatic tumor cells; COX-2–linked selectivity enables tumor-restricted replication, inducing oncolysis and immunogenic cell death after endoscopic ultrasound–guided intratumoral injection.
nci_thesaurus_concept_id
C204861
nci_thesaurus_preferred_term
RGD-modified COX-2 Promoter-controlled Conditionally Replicative Adenovirus RGDCRAdCox2F
nci_thesaurus_definition
A conditionally replicative, oncolytic adenovirus type 5 (Ad5), with potential oncolytic activity. Arg-Gly-Asp (RGD)-modified cyclooxygenase (COX)-2 promoter-controlled conditionally replicative adenovirus (CRAd) RGDCRAdCox2F has been engineered to replace the original E1 region with a COX-2 promoter-controlled E1 expression cassette, and to include RGD modification of the fiber protein. Upon administration, the RGD motif of RGD-modified COX-2 CRAd RGDCRAdCox2F binds to integrins expressed on tumor cells. This results in the replication of the oncolytic adenovirus in tumor cells, which induces selective adenovirus-mediated cytotoxicity in tumor cells and leads to tumor cell lysis. Following the lysis of the infected cells, the oncolytic virus is released and infects adjacent cells. This induces further tumor cell oncolysis. The lysis of tumor cells also results in the release of tumor-associated antigens (TAAs) and inflammatory mediators, which may activate the immune system to mount an anti-tumor immune response. RGD modification of the fiber protein enhances the infectivity of the oncolytic virus. COX-2 promoter-controlled E1 expression regulates the replication of the oncolytic virus as COX-2 is overexpressed in gastrointestinal malignancies.
drug_mesh_term
Oncolytic Viruses
drug_category
ONCOLYTIC VIRUS
drug_class
Other treatment
drug_delivery_route
Intratumoral
drug_mechanism_of_action
RGDCRAdCOX2F is a conditionally replicative adenovirus engineered with an RGD-modified fiber to enter tumor cells via alpha v integrins (e.g., alpha v beta 3/alpha v beta 5). E1 expression is driven by a COX-2 promoter to restrict replication to COX-2–overexpressing tumors, resulting in selective intratumoral viral amplification, direct oncolysis, and immunogenic cell death with release of tumor antigens that can elicit anti-tumor immune responses.
drug_name
RGDCRAdCOX2F
nct_id_drug_ref
NCT06693986